“…ECMO is a first-line device that 'covers' biventricular and lung function, fits almost all patients and clinical scenarios, offers variability of cannulation (central, peripheral), is rapidly deployable, versatile, familiar, and economical [4 ,12,33,52,57]. Although improved ECMO technology has contributed to improved 'time and team-dependent' results[10,12,14,25,26,29,44,52,66,67,69], according to larger-scale data[4 ,5,13,15,16,60,64,65,102] and expert opinion the 'overall survival remains persistently poor after ECMO support, despite maintaining systemic blood flow and oxygenation. Until we understand how to prevent vital organ injury, this will not change'[109].ECMO disadvantages include blood trauma inside the oxygenator, systemic inflammatory response triggering, increased anticoagulation, inadequate left heart unloading in severe left-ventricular failure, shorter support duration, decreased mobilization, potential for extubation and oral feeding[4 ,5,12,14-16,40].…”